Background Thrombocytopenia may be a dose-dependent adverse effect of linezolid
therapy. Objectives To assess whether proactive therapeutic drug monitoring (TDM) could …

Objectives Prolonged treatment with linezolid may cause toxicity. The purpose of this study
was to define pharmacodynamic thresholds for improving safety outcomes of linezolid …

We assessed whether prospective therapeutic drug monitoring to optimise the therapeutic
range could prevent linezolid-induced thrombocytopenia. This prospective interventional …

Objectives Thrombocytopenia is sometimes observed during linezolid therapy. Here, we
aimed to investigate the factors affecting linezolid-induced thrombocytopenia. Methods A …

The objective of the present retrospective observational study carried out in patients
receiving a standard dosage of linezolid and undergoing routine therapeutic drug …

Background Linezolid is a broad-spectrum antimicrobial with limited use due to toxicity. This
study aimed to evaluate linezolid toxicity in a large multicentre cohort. Secondary objectives …

The major adverse event associated with linezolid treatment is thrombocytopenia. This study
investigated risk factors associated with the development of thrombocytopenia in patients …

Background Thrombocytopenia is a well-recognized adverse effect of linezolid; however, the
frequency of this adverse effect during therapy has been variable across previous studies …

The pharmacokinetic/pharmacodynamic (PK/PD) index for the efficacy of linezolid is a 24-h
area under the plasma drug concentration–time curve (AUC 24)/minimum inhibitory …

Some studies have shown that adjustments to the linezolid dose guided by therapeutic drug
monitoring (TDM) can reduce interindividual variability in drug exposure and improve …